0039  />

Figure 2. Correlation between the urinary equol concentrations measured employing the HPLC method and the ELISA method using different combinations of (R,S)-equol and S-equol for the standard and enzyme-labeled antigen.

Table 2. Cross-reactivity of the equol ELISA compared between Methods 2 and 5.

collected. The standard curve showed a favorable line within a range of 36.3 - 8910 ng/ml (Figure 3). On precision profile analysis the concentration at which the coefficient of variation (CV) was lower than 10% was 330 ng/ml (data not shown), based on which the measurement range was set at 330 - 8910 ng/ml. When 1 volume of equol at a known concentration was added to 9 volumes of urine, the recovery rate of equol was 71.1- 121.9% (Table 3). The CVs of the intraand inter-assay reproducibility of human urinary equol (537 - 4008 ng/ml) measurement was 6.2% - 8.1% (n = 8) and 3.5% - 4.0% (n = 12), respectively (Table 4).

The time-course change in urinary equol concentration after isoflavone ingestion was measured as a clinical application model (Figure 4). The urinary equol concentration reached its first peak of 790 ng/ml at 12.5 hours after isoflavone ingestion and then declined to below the detection limit at 14 hours. The concentration increased again, to 475 ng/ml at 16 hours, then reached its second peak of 729 ng/ml at 30.5 hours, and declined below the detection limit at 37 hours. The appearance of two peaks in the urinary equol level may have been due to enterohepatic circulation [19].

4. Conclusion

In this study we developed S-equol diastereomer specific ELISA (Method 5) by selecting S-equol for both the standard and the antigen labeled enzyme, which was improved from another novel invention of the simple ELISA (Method 1). Since the simple ELISA (Method 1) can measure equol without the deconjugation process, measuring equol in urine sample became more convenient, and its application for other methods such as immunochromatography is expected.

Since the specific ELISA (Method 5) not only shows a low cross reaction to R-equol and daidzein but also handles a large number of samples within a short period of time, the laboratory possessing only general equipments are able to carry out the studies on equol without special apparatus used for HPLC and LC/MS/MS. The utilizetion of this method in broad fields including epidemiological and biokinetic studies is expected.

We prepared antiserum with low stereospecificity, instead of S-equol-specific antibody by immuni-zation with

Figure 3. Standard curve of S-equol measured by the S-equol specific ELISA (n = 16, mean ± 2.6 SD).

Table 3. Recovery test using urine samples in the S-equol specific ELISA.

Table 4. Reproducibility in the S-equol Specific ELISA.

Figure 4. Time-course changes in the urinary equol concentration. The urinary equol concentration was measured before and after the ingestion intake of a soybean bar containing 19 mg of isoflavone, regarding the time of ingestion as 0 hour.

(R,S)-equol, and developed an S-equol-specific immunoassay system by a combination of S-equol HRP conjugate and this low stereospecific antiserum. This system is expected to be applied for a simple stereospecific immunoassay in which specific antibody preparation is difficult.


  1. A. M. Duncan, B. E. Merz-Demlow, X. Xu, W. R. Phipps and M. S. Kurzer, “Premenopausal Equol Excretors Show Plasma Hormone Profiles Associated with Lowered Risk of Breast Cancer,” Cancer Epidemiology, Biomarkers and Prevention, Vol. 9, No. 6, 2000, pp. 581-586.
  2. H. Akaza, N. Miyanaga, N. Takashima, S. Naito, Y. Hirao, T. Tsukamoto, T. Fujioka, M. Mori, W. J. Kim, J. M. Song and A. J. Pantuck, “Comparisons of Percent Equol Producers between Prostate Cancer Patients and Controls: Case-Controlled Studies of Isoflavones in Japanese, Korean and American Residents,” Japanese Journal of Clinical Oncology, Vol. 34, No. 2, 2004, pp. 86-89. doi:10.1093/jjco/hyh015
  3. H. Akaza, N. Miyanaga, N. Takashima, S. Naito, Y. Hirao, T. Tsukamoto and M. Mori, “Is Daidzein NonMetabolizer a High Risk for Prostate Cancer? A CaseControlled Study of Serum Soybean Isoflavone Concentration,” Japanese Journal of Clinical Oncology, Vol. 32, No. 8, 2002, pp. 296-300. doi:10.1093/jjco/hyf064
  4. K. Ozasa, M. Nakao, Y. Watanabe, K. Hayashi, T. Miki, K. Mikami, M. Mori, F. Sakauchi, M. Washio, Y. Ito, K. Suzuki, K. Wakai, A. Tamakoshi and JACC Study Group, “Serum Phytoestrogens and Prostate Cancer Risk in a Nested Case-Control Study among Japanese Men,” Cancer Science, Vol. 95, No. 1, 2004, pp. 65-71. doi:10.1111/j.1349-7006.2004.tb03172.x
  5. K. D. Setchell, N. M. Brown and E. Lydeking-Olsen, “The Clinical Importance of the Metabolite Equol-A Clue to the Effectiveness of Soy and Its Isoflavones,” Journal of Nutrition, Vol. 132, No. 12, 2002, pp. 3577-3584.
  6. T. Ueno, S. Uchiyama and N. Kikuchi, “The Role of Intestinal Bacteria on Biological Effects of Soy Isoflavones in Human,” Journal of Nutrition, Vol. 132, 2002, p. 594S.
  7. E. Lydeking-Olsen, J. B. E. Jensen, K. D. R. Setchell, M. Damhus and T. H. Jensen, “Isoflavone-Rich Soymilk Prevents Bone-Loss in the Lumbar Spine of Postmenopausal Women. A 2 Year Study,” Journal of Nutrition, Vol. 132, 2002, p. 581S.
  8. T. Maruo, M. Sakamoto, C. Ito, T. Toda and Y. Benno, “Adlercreutzia Equolifaciens gen. nov., sp. nov., an Equol-Producing Bacterium Isolated from Human Faeces, and Emended Description of the Genus Eggerthella,” International Journal of Systematic and Evolutionary Microbiology, Vol. 58, Pt. 5, 2008, pp. 1221-1227.
  9. S. Uchiyama, T. Ueno and T. Suzuki, “Identification of a Newly Isolated Equol-Producing Lactic Acid Bacterium from the Human Feces,” Journal of Intestinal Microbiology, Vol. 21, No. 3, 2007, pp. 217-220 [in Japanese].
  10. K. Hirayama, “Metabolism of Soy Isoflavones by Intestinal Flora,” Journal of Intestestinal Microbiology, Vol. 19, No. 1, 2005, pp. 17-23 [in Japanese].
  11. T. J. Lundh, H. Pettersson and K.H. Kiessling, “Liquid Chromatographic Determination of the Estrogens Daidzein, Formononetin, Coumestrol, and Equol in Bovine Blood Plasma and Urine,” Journal of the Association of Official Analytical Chemists, Vol. 71, No. 5, 1988, pp. 938-941.
  12. A. A. Franke and L. J. Custer, “High-Performance Liquid Chromatographic Assay of Isoflavonoids and Coumestrol from Human Urine,” Journal of Chromatography B: Biomedical Sciences and Applications, Vol. 662, No. 1, 1994, pp. 47-60. doi:10.1016/0378-4347(94)00390-4
  13. L. Coward, M. Kirk, N. Albin and S. Barnes, “Analysis of Plasma Isoflavones by Reversed-Phase HPLC-Multiple Reaction Ion Monitoring-Mass Spectrometry,” Clinica Chimica Acta, Vol. 247, No. 1-2, 1996, pp. 121-142. doi:10.1016/0009-8981(95)06242-4
  14. E. Brouwers, R. L’homme, N. Al-Maharik, O. Lapcík, R. Hampl, K. Wähälä, H. Mikola and H. Adlercreutz, “Time-Resolved Fluoroimmunoassay for Equol in Plasma and Urine,” Journal of Steroid Biochemistry and Molecular Biology, Vol. 84, No. 5, 2003, pp. 577-588. doi:10.1016/S0960-0760(03)00071-2
  15. D. C. Talbot, R. M. Ogborne, T. Dadd, H. Adlercreutz, G. Barnard, S. Bugel, F. Kohen, S. Marlin, J. Piron, A. Cassidy and J. Powell, “Monoclonal Antibody-Based Time-Resolved Fluorescence Immunoassays for Daidzein, Genistein, and Equol in Blood and Urine: Application to the Isoheart Intervention Study,” Clinical Chemistry, Vol. 53, No. 4, 2007, pp. 748-756. doi:10.1373/clinchem.2006.075077
  16. T. Minekawa, A. Kambegawa, K. Shindome, H. Ohkuma, K. Abe, H. Maekawa and H. Arakawa. “Development of Bioluminescent Enzyme Immunoassay for S-Equol Using Firefly Luciferase and Its Application to the Assessment of Equol-Producer Status,” Chemical and Pharmaceutical Bulletin, Vol. 59, No. 1, 2011, pp. 84-87. doi:10.1248/cpb.59.84
  17. H. Adlercreutz, J. van der Wildt, J. Kinzel, H. Attalla, K. Wähälä, T. Mäkelä, T. Hase and T. Fotsis, “Lignan and Isoflavonoid Conjugates in Human Urine,” Journal of Steroid Biochemistry and Molecular Biology, Vol. 52, No. 1, 1995, pp. 97-103. doi:10.1016/0960-0760(94)00146-D
  18. K. D. Setchell, C. Clerici, E. D. Lephart, S. J. Cole, C. Heenan, D. Castellani, B. E. Wolfe, L. NechemiasZimmer, N. M. Brown, T. D. Lund, R. J. Handa and J. E. Heubi, “S-Equol, a Potent Ligand for Estrogen Receptor Beta, Is the Exclusive Enantiomeric form of the Soy Isoflavone Metabolite Produced by Human Intestinal Bacterial Flora,” The American Journal of Clinical Nutrition, Vol. 81, No. 5, 2005, pp. 1072-1079.
  19. K. D. Setchell, N. M. Brown, P. Desai, L. ZimmerNechemias, B. E. Wolfe, W. T. Brashear, A. S. Kirschner, A. Cassidy and J. E. Heubi, “Bioavailability of Pure Isoflavones in Healthy Humans and Analysis of Commercial Soy Isoflavone Supplements,” Journal of Nutrition, Vol. 131, No. 4-Suppl, 2001, pp. 1362S-1375.

Journal Menu >>